Chadi hosts Dr. Neal Shore, a urologic oncologist who became heavily involved in GU oncology research – including trials that incorporate systemic chemotherapy. Dr. Shore has a unique practice where he and his staff deliver chemotherapy when appropriate. Chadi was intrigued by this setting as medical oncologists are the ones customarily delivering chemotherapy, and invited him to the show to share how this all started, its pros and cons, and the impact on patients.
Dr. Shore explains how the field has seen drastic changes since the early 1990’s, why he decided to spearhead bringing clinical research into his community clinic, and how his clinic is staffed and structured to support a functioning and successful research hub. Then, the discussion pivots to his recently published clinical trial, ENACT, and the controversy surrounding use of enzalutamide monotherapy in low- or intermediate-risk prostate cancer. There’s been so much controversy and backlash about the ENACT trial that Chadi had to ask him about it and his reaction to what happened when the article was published.
Leading into the ASH Annual Meeting, Dr. Kami Maddocks, professor in the Division of Hematology at The Ohio State University and medical director of infusion services at The James Comprehensive Cancer Center, provides an in-depth analysis of advancements in non-Hodgkin lymphoma care, with a focus on aggressive B-cell lymphoma. She explores the evolving roles of
Dr. Vivek Subbiah returns for another edition of Vivek’s Takes, sharing his insights on key updates from ESMO Congress 2024, including breakthroughs in neuroendocrine tumors, gastric cancer, and non-small cell lung cancer. He also delves into the highlights of his AACR debate on integrating early cancer detection with AI, arguing for the transformative potential of
Chadi welcomes Dr. Andrea Apolo, an internationally recognized leader in bladder cancer research from the National Cancer Institute. Dr. Apolo shares her expertise on recent advancements in urothelial cancer therapy, including key breakthroughs in checkpoint inhibition that have marked a significant turning point in treatment. The conversation delves into optimal sequencing and combination strategies for
